ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2023

SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy.

Dominique Croteau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.